MX2020014245A - Inhibidores de quinasas dependientes de ciclinas. - Google Patents

Inhibidores de quinasas dependientes de ciclinas.

Info

Publication number
MX2020014245A
MX2020014245A MX2020014245A MX2020014245A MX2020014245A MX 2020014245 A MX2020014245 A MX 2020014245A MX 2020014245 A MX2020014245 A MX 2020014245A MX 2020014245 A MX2020014245 A MX 2020014245A MX 2020014245 A MX2020014245 A MX 2020014245A
Authority
MX
Mexico
Prior art keywords
cyclin
inhibitors
dependent kinases
compounds
kinases
Prior art date
Application number
MX2020014245A
Other languages
English (en)
Inventor
Stephen W Kaldor
Eric A Murphy
Toufike Kanouni
Lee D Arnold
John Tyhonas
Original Assignee
Kinnate Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kinnate Biopharma Inc filed Critical Kinnate Biopharma Inc
Publication of MX2020014245A publication Critical patent/MX2020014245A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Abstract

Inhibidores de quinasas dependientes de ciclinas (CDK), composiciones farmacéuticas que comprenden dichos compuestos y métodos para su utilización en el tratamiento de enfermedades.
MX2020014245A 2018-06-29 2019-06-28 Inhibidores de quinasas dependientes de ciclinas. MX2020014245A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862691879P 2018-06-29 2018-06-29
PCT/US2019/039959 WO2020006497A1 (en) 2018-06-29 2019-06-28 Inhibitors of cyclin-dependent kinases

Publications (1)

Publication Number Publication Date
MX2020014245A true MX2020014245A (es) 2021-05-12

Family

ID=68985220

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020014245A MX2020014245A (es) 2018-06-29 2019-06-28 Inhibidores de quinasas dependientes de ciclinas.

Country Status (14)

Country Link
US (2) US10894788B2 (es)
EP (1) EP3813819A4 (es)
JP (1) JP2021529740A (es)
KR (1) KR20210040368A (es)
CN (1) CN112638373A (es)
AR (1) AR115646A1 (es)
AU (1) AU2019291935A1 (es)
BR (1) BR112020026748A2 (es)
CA (1) CA3104131A1 (es)
IL (1) IL279791A (es)
MX (1) MX2020014245A (es)
SG (1) SG11202013175SA (es)
TW (1) TW202016094A (es)
WO (1) WO2020006497A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3787629A4 (en) 2018-05-02 2022-01-05 Kinnate Biopharma Inc. INHIBITORS OF CYCLINE-DEPENDENT KINASES
CA3104131A1 (en) 2018-06-29 2020-01-02 Kinnate Biopharma Inc. Inhibitors of cyclin-dependent kinases
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
US11384083B2 (en) 2019-02-15 2022-07-12 Incyte Corporation Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors
US11472791B2 (en) 2019-03-05 2022-10-18 Incyte Corporation Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors
US11919904B2 (en) 2019-03-29 2024-03-05 Incyte Corporation Sulfonylamide compounds as CDK2 inhibitors
US11447494B2 (en) 2019-05-01 2022-09-20 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
US11440914B2 (en) 2019-05-01 2022-09-13 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
CN114401955A (zh) * 2019-07-17 2022-04-26 金耐特生物制药公司 细胞周期蛋白依赖性激酶的抑制剂
KR20220064369A (ko) 2019-08-14 2022-05-18 인사이트 코포레이션 Cdk2 저해제로서의 이미다졸릴 피리디미딘일아민 화합물
CA3157681A1 (en) 2019-10-11 2021-04-15 Incyte Corporation Bicyclic amines as cdk2 inhibitors
AU2020417223A1 (en) * 2019-12-31 2022-07-14 Kinnate Biopharma Inc. Treatment of cancer with CDK12/13 inhibitors
WO2023102184A1 (en) * 2021-12-03 2023-06-08 Incyte Corporation Bicyclic amine compounds as cdk12 inhibitors
WO2024032561A1 (en) * 2022-08-08 2024-02-15 Insilico Medicine Ip Limited Inhibitors of cyclin-dependent kinase (cdk) 12 and/or cdk13 and uses thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994001113A1 (en) * 1992-07-02 1994-01-20 Otsuka Pharmaceutical Company, Limited Oxytocin antagonist
US6334997B1 (en) 1994-03-25 2002-01-01 Isotechnika, Inc. Method of using deuterated calcium channel blockers
KR20040068613A (ko) 1994-03-25 2004-07-31 이소테크니카 인코포레이티드 중수소화된 화합물 이를 포함하는 고혈압 치료용 조성물
US20070004763A1 (en) 2005-06-10 2007-01-04 Nand Baindur Aminoquinoline and aminoquinazoline kinase modulators
WO2013020062A1 (en) 2011-08-04 2013-02-07 Array Biopharma Inc. Quinazoline compounds as serine/threonine kinase inhibitors
US20140309184A1 (en) 2011-09-21 2014-10-16 University Of South Alabama Methods and compositions for the treatment of ovarian cancer
US9382239B2 (en) 2011-11-17 2016-07-05 Dana-Farber Cancer Institute, Inc. Inhibitors of c-Jun-N-terminal kinase (JNK)
US20160264551A1 (en) 2013-10-18 2016-09-15 Syros Pharmaceuticals, Inc. Heteroaromatic compounds useful for the treatment of prolferative diseases
EP3057954A2 (en) * 2013-10-18 2016-08-24 Syros Pharmaceuticals, Inc. Heteromaromatic compounds useful for the treatment of proliferative diseases
GB201403093D0 (en) 2014-02-21 2014-04-09 Cancer Rec Tech Ltd Therapeutic compounds and their use
TWI601712B (zh) * 2014-11-05 2017-10-11 達特神經科學（開曼）有限責任公司 作為ｇｌｙｔ１抑制劑之經取代之氮雜環丁基化合物
AU2015371251B2 (en) 2014-12-23 2020-06-11 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
AU2016243529B2 (en) * 2015-03-27 2021-03-25 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
MY190459A (en) 2015-06-04 2022-04-21 Aurigene Discovery Tech Ltd Substituted heterocyclyl derivatives as cdk inhibitors
CA2986441A1 (en) 2015-06-12 2016-12-15 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
WO2016210296A1 (en) * 2015-06-26 2016-12-29 Dana-Farber Cancer Institute, Inc. 4,6-pyrimidinylene derivatives and uses thereof
JP7028766B2 (ja) 2015-09-09 2022-03-02 ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド サイクリン依存性キナーゼの阻害剤
GB201605126D0 (en) 2016-03-24 2016-05-11 Univ Nottingham Inhibitors and their uses
CA3047136A1 (en) * 2016-12-19 2018-06-28 Isocure Biosciences Inc. Inhibitors of mutant isocitrate dehydrogenases and compositions and methods thereof
WO2019035866A1 (en) * 2017-08-15 2019-02-21 The Brigham & Women's Hospital, Inc. COMPOSITIONS AND METHODS FOR TREATING THE TUBEROUS SCLEROSIS COMPLEX
GB201715342D0 (en) 2017-09-22 2017-11-08 Univ Nottingham Compounds
EP3787629A4 (en) 2018-05-02 2022-01-05 Kinnate Biopharma Inc. INHIBITORS OF CYCLINE-DEPENDENT KINASES
CA3104131A1 (en) 2018-06-29 2020-01-02 Kinnate Biopharma Inc. Inhibitors of cyclin-dependent kinases
CN114401955A (zh) 2019-07-17 2022-04-26 金耐特生物制药公司 细胞周期蛋白依赖性激酶的抑制剂
AU2020417223A1 (en) 2019-12-31 2022-07-14 Kinnate Biopharma Inc. Treatment of cancer with CDK12/13 inhibitors

Also Published As

Publication number Publication date
IL279791A (en) 2021-03-01
US20210130340A1 (en) 2021-05-06
AR115646A1 (es) 2021-02-10
AU2019291935A1 (en) 2021-02-04
CN112638373A (zh) 2021-04-09
TW202016094A (zh) 2020-05-01
SG11202013175SA (en) 2021-01-28
US11390618B2 (en) 2022-07-19
BR112020026748A2 (pt) 2021-03-30
US10894788B2 (en) 2021-01-19
WO2020006497A1 (en) 2020-01-02
JP2021529740A (ja) 2021-11-04
US20200024266A1 (en) 2020-01-23
KR20210040368A (ko) 2021-04-13
CA3104131A1 (en) 2020-01-02
EP3813819A1 (en) 2021-05-05
EP3813819A4 (en) 2022-08-17

Similar Documents

Publication Publication Date Title
MX2020014245A (es) Inhibidores de quinasas dependientes de ciclinas.
MX2020008559A (es) Compuestos heterocíclicos como inhibidores de la quinasa.
JOP20220087A1 (ar) أمينات ثنائية الحلقة كمثبطات لـ cdk2
MX2022001940A (es) Compuestos de imidazolil pirimidinilamina como inhibidores de cdk2.
MX2022004937A (es) Inhibidores de las cinasas raf.
MX2019001125A (es) Inhibidores de cinasa macrociclica.
PH12020551043A1 (en) Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues
MX2017015574A (es) Inhibidores de tirosina quinasa de bruton.
TW201613919A (en) Inhibitors of Bruton's tyrosine kinase
MX2016015565A (es) Ciertos inhibidores de la proteina quinasa.
MX2019007243A (es) Inhibidores de ectonucleotidasa y metodos de uso de los mismos.
PH12020552214A1 (en) Ectonucleotidase inhibitors and methods of use thereof
PH12019502646A1 (en) Pyrazole magl inhibitors
MX2023002507A (es) Inhibidores de cd73.
AU2018347307A1 (en) Heterocyclic compounds and uses thereof
EP3790867A4 (en) KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE
MX2020010116A (es) Compuestos macrociclicos como inhibidores de quinasas del receptor de tropomiosina (trk).
MX2017013875A (es) Ciertos inhibidores de la proteína quinasa.
JOP20190262B1 (ar) مثبطات بيرازول magl
NZ788133A (en) Cd73 inhibitors
MX2020000135A (es) Nuevos compuestos de quinolinona.
MX2021013602A (es) Inhibidores de jak.
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
MX2018013573A (es) Ciertos inhibidores de la proteína cinasa.
MX2021003643A (es) Derivados de terpenoides y usos de los mismos.